IL130424A - Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis - Google Patents

Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis

Info

Publication number
IL130424A
IL130424A IL13042496A IL13042499A IL130424A IL 130424 A IL130424 A IL 130424A IL 13042496 A IL13042496 A IL 13042496A IL 13042499 A IL13042499 A IL 13042499A IL 130424 A IL130424 A IL 130424A
Authority
IL
Israel
Prior art keywords
preparation
ziprasidone
medicaments
compositions
hydrochloride monohydrate
Prior art date
Application number
IL13042496A
Other languages
English (en)
Other versions
IL130424A0 (en
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130424(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL130424A0 publication Critical patent/IL130424A0/xx
Publication of IL130424A publication Critical patent/IL130424A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL13042496A 1998-06-15 1999-06-10 Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis IL130424A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
IL130424A0 IL130424A0 (en) 2000-06-01
IL130424A true IL130424A (en) 2003-10-31

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13042496A IL130424A (en) 1998-06-15 1999-06-10 Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis

Country Status (44)

Country Link
US (1) US6150366A (is)
EP (1) EP0965343B1 (is)
JP (2) JP3441676B2 (is)
KR (1) KR100338915B1 (is)
CN (1) CN1307994C (is)
AP (1) AP1216A (is)
AR (1) AR015553A1 (is)
AT (1) ATE240732T1 (is)
AU (1) AU753820B2 (is)
BG (1) BG64691B1 (is)
BR (1) BR9902268A (is)
CA (1) CA2274338C (is)
CO (1) CO5070579A1 (is)
CY (1) CY2003002I1 (is)
CZ (1) CZ297954B6 (is)
DE (1) DE69908021T2 (is)
DK (1) DK0965343T3 (is)
EA (1) EA002223B1 (is)
ES (1) ES2197581T3 (is)
GT (1) GT199900080A (is)
HN (1) HN1999000089A (is)
HR (1) HRP990193B1 (is)
HU (1) HU226487B1 (is)
ID (1) ID23546A (is)
IL (1) IL130424A (is)
IS (1) IS2182B (is)
MA (1) MA26647A1 (is)
MY (1) MY121397A (is)
NO (1) NO316713B1 (is)
NZ (1) NZ336271A (is)
OA (1) OA11064A (is)
PA (1) PA8475601A1 (is)
PE (1) PE20000632A1 (is)
PL (2) PL195209B1 (is)
PT (1) PT965343E (is)
RS (1) RS49611B (is)
SG (1) SG77243A1 (is)
SI (1) SI0965343T1 (is)
SK (1) SK286245B6 (is)
TR (1) TR199901379A2 (is)
TW (1) TW590774B (is)
UA (1) UA59383C2 (is)
UY (1) UY25649A1 (is)
ZA (1) ZA993938B (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
PL196867B1 (pl) * 1999-05-27 2008-02-29 Pfizer Prod Inc Kompozycja zyprazydonu
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
MXPA04011203A (es) * 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
CA2543805A1 (en) * 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
EP1687300A4 (en) * 2003-11-28 2007-08-01 Wockhardt Ltd PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE
CA2550485A1 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
EP1748776A1 (en) * 2004-05-03 2007-02-07 Duke University Compositions for affecting weight loss
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
CA2577852A1 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2008538751A (ja) * 2005-04-13 2008-11-06 ファイザー・プロダクツ・インク ナノ粒子組成物を持続放出するための注射用デポ製剤および方法
PE20061318A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
DK1884242T3 (da) 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
WO2009116085A2 (en) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. An improved process for the preparation of ziprasidone
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
SMT201900650T1 (it) 2010-02-25 2020-01-14 Pfizer Formulazioni di apixaban
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
ATE254600T1 (de) * 1996-02-13 2003-12-15 Pfizer Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed

Also Published As

Publication number Publication date
IL130424A0 (en) 2000-06-01
HN1999000089A (es) 1999-11-03
KR100338915B1 (ko) 2002-05-30
PL333737A1 (en) 1999-12-20
EA002223B1 (ru) 2002-02-28
NO992892D0 (no) 1999-06-14
PT965343E (pt) 2003-08-29
ES2197581T3 (es) 2004-01-01
AP1216A (en) 2003-10-19
OA11064A (en) 2002-03-13
TR199901379A2 (xx) 2000-01-21
AU753820B2 (en) 2002-10-31
GT199900080A (es) 2000-11-29
MY121397A (en) 2006-01-28
PA8475601A1 (es) 2000-09-29
HUP9901960A3 (en) 2000-09-28
HRP990193B1 (en) 2003-08-31
PL195606B1 (pl) 2007-10-31
HU226487B1 (en) 2009-03-02
KR20000006143A (ko) 2000-01-25
BR9902268A (pt) 2000-05-02
AU3398399A (en) 1999-12-23
NO992892L (no) 1999-12-16
IS5079A (is) 1999-12-16
EA199900467A3 (ru) 2000-04-24
TW590774B (en) 2004-06-11
CZ297954B6 (cs) 2007-05-09
MA26647A1 (fr) 2004-12-20
BG64691B1 (bg) 2005-12-30
ID23546A (id) 2000-05-04
CN1242987A (zh) 2000-02-02
SI0965343T1 (en) 2003-10-31
HU9901960D0 (en) 1999-08-30
EA199900467A2 (ru) 1999-12-29
HRP990193A2 (en) 2000-02-29
CO5070579A1 (es) 2001-08-28
ZA993938B (en) 2000-12-14
ATE240732T1 (de) 2003-06-15
CY2003002I1 (el) 2009-11-04
DE69908021D1 (de) 2003-06-26
HUP9901960A2 (hu) 2000-08-28
UY25649A1 (es) 2000-02-23
SK286245B6 (sk) 2008-06-06
SK76999A3 (en) 2000-12-11
DK0965343T3 (da) 2003-08-04
UA59383C2 (uk) 2003-09-15
EP0965343A2 (en) 1999-12-22
NZ336271A (en) 2000-10-27
PL195209B1 (pl) 2007-08-31
PE20000632A1 (es) 2000-07-26
AR015553A1 (es) 2001-05-02
NO316713B1 (no) 2004-04-13
US6150366A (en) 2000-11-21
AP9901579A0 (en) 1999-06-30
YU27199A (sh) 2002-12-10
DE69908021T2 (de) 2003-11-27
JP3441676B2 (ja) 2003-09-02
SG77243A1 (en) 2000-12-19
RS49611B (sr) 2007-06-04
JP2002003492A (ja) 2002-01-09
IS2182B (is) 2006-12-15
CZ212799A3 (cs) 2000-09-13
HK1024184A1 (en) 2000-10-05
JP4187423B2 (ja) 2008-11-26
CA2274338A1 (en) 1999-12-15
JP2000007566A (ja) 2000-01-11
CA2274338C (en) 2003-04-15
BG103489A (en) 2000-07-31
EP0965343B1 (en) 2003-05-21
CN1307994C (zh) 2007-04-04
EP0965343A3 (en) 2000-02-23

Similar Documents

Publication Publication Date Title
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
IL193615A0 (en) New azaindoles for inhibiting protein kinases and pharmaceutical composition comprising the same
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
AU4468201A (en) External preparation for the skin and beautifying agents
HUP0202897A3 (en) Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them
HUS1300061I1 (hu) Herbicid kompozíció
IL155071A0 (en) Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
HUP0202648A3 (en) Imidazolyl derivatives, pharmaceutical compositions containing them and their use
HUP0200155A3 (en) Thioamide derivatives, pharmaceutical compositions containing them and their use
NZ514062A (en) Diaryl derivatives and their use as medicaments
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
HUP0102585A3 (en) Thienylazolylalcoxyethanamin derivatives preparation the same and their use as medicaments
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP0200441A3 (en) Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP9803040A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees